Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks
A phase 3 clinical trial led by a Massachusetts General Hospital (MGH) physician, finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema (HAE)—a rare, potentially life-threatening ...
Nov 27, 2018
0
0